Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoogerwaard, E. M.
Right arrow Articles by de Visser, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoogerwaard, E. M.
Right arrow Articles by de Visser, M.
Related Collections
Right arrow Muscle disease
Right arrow All Genetics
NEUROLOGY 2005;65:1984-1986
© 2005 American Academy of Neurology
Brief Communications

Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy

Edo M. Hoogerwaard, MD, PhD, Ieke B. Ginjaar, PhD, Egbert Bakker, PhD and Marianne de Visser, MD, PhD

From the Department of Neurology (Drs. Hoogerwaard and de Visser), Academic Medical Centre, University of Amsterdam; and Department of Human and Clinical Genetics (Drs. Ginjaar and Bakker), Leiden University Medical Center, The Netherlands. Dr. Hoogerwaard is currently with the Department of Neurology, Rijnstate Hospital, Arnhem.

Address correspondence and reprint requests to Dr. Edo M. Hoogerwaard, Rijnstate Hospital, PO Box 9555, 6800 TA Arnhem, The Netherlands; e-mail: ehoogerwaard{at}hccnet.nl

Associations between clinical phenotype (muscle weakness, dilated cardiomyopathy) and dystrophin abnormalities in muscle tissue among definite carriers of Duchenne (DMD) and Becker muscular dystrophy (BMD) were investigated. No associations between dystrophin abnormalities and clinical variables in DMD/BMD carriers were found. Because 26% of nonmanifesting carriers have dystrophin-negative fibers, this might be used in suspected DMD/BMD carriers in whom DNA analysis fails to give an answer about their carrier risk.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 27 issue to find the title link for this article.

Disclosure: The authors report no conflicts of interest.

Received April 4, 2003. Accepted in final form August 29, 2005.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.